Showing 2828 results for "hemophilia"

Losing a Legend: Barry Haarde Passes Away at 52

The bleeding disorder community has suffered an unimaginable loss: Barry Haarde, the founder of the “Wheels for the World” campaign, passed away over the weekend. Haarde was just 52 years old. MORE: New documentary explores what it’s like living with a bleeding disorder Barry Haarde was born with severe…

Miniature Bleeding Model May Help Research into Wound Healing, Blood Disorders

Researchers at Emory University School of Medicine have developed a small-scale model system to study bleeding and clotting of wounds. The miniature model also accurately reproduces the alterations observed in hemophilia A patients. Their work, “A microengineered vascularized bleeding model that integrates the principal components of hemostasis”, was published in…

The Hemo Mama Bear Olympics

There are some moments in my life while raising two sons with severe hemophilia that I have thought, “Wow! You, Cazandra, have just won the gold medal in the Hemo Mama Bear Olympics!” And there are other times I failed so miserably that I would not have even…

Practice Makes Perfect

I’m not a football fan, but I do watch the Super Bowl to see the halftime show and the commercials. This year’s game was a good one. I will admit the game riveted me toward the end. When the Philadelphia Eagles kicked their final field goal, stretching their lead…

How to Create a Family Emergency Kit

The National Center on Birth Defects and Development Disabilities has an online booklet that helps hemophilia patients and their families construct a plan in the event of an emergency. MORE: Initial results from phase 3 hemophilia trial of Emicizumab in children looks promising The plan focuses on all…

Fitusiran Clinical Development Among 2018 Corporate Goals, Alnylam Pharmaceuticals Says

Among its corporate goals for 2018 announced recently, Alnylam Pharmaceuticals said it will continue to clinically develop the investigational RNA therapy fitusiran to treat hemophilia. Fitusiran, also known as ALN-AT3SC, is an RNAi therapeutic agent that targets a protein called antithrombin — which inhibits blood clotting — while increasing production of the…